Cargando…
Pseudo progression in heterogeneity of right-sided metastatic colon carcinoma during nivolumab therapy: A case report
RATIONALE: Pseudo progression is a noted phenomenon of immune checkpoint inhibitors therapy, which has been defined as a response after an initial enlargement of the tumor followed by tumor reduction. In July 2017, the Food and Drug Administration granted accelerated approval of nivolumab for the tr...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709191/ https://www.ncbi.nlm.nih.gov/pubmed/31393352 http://dx.doi.org/10.1097/MD.0000000000016490 |